Edrophonium
(Tensilon, Reversol, Enlon) |
Category:
Description:
Indications:
-
Curare
antidote
-
Diagnosis
of myasthenia gravis
-
Differentiate
between cholinergic crisis and myasthenia gravis crisis
-
Evaluation
of treatment requirements in myasthenia gravis
Contraindications:
Precautions:
-
Pregnancy
category C; ionized at physiologic pH, not expected to cross placental
barrier or excreted in breast milk
-
May
cause premature labor
-
Seizure
disorders, bronchial asthma, recent coronary occlusion,
hyperthyroidism
-
Dysrhythmias,
peptic ulcer, megacolon, poor GI motility, bradycardia, hypotension
Adverse
Reactions (Side Effects):
-
CNS:
dizziness, drowsiness, headache, incoordination, seizures, sweating,
paralysis, weakness, loss of consciousness
-
CV:
AV block, bradycardia, cardiac arrest, dysrhythmias, , syncope,
hypotension, tachycardia
-
EENT:
blurred vision, lacrimation, miosis, visual changes
-
GI:
cramps, diarrhea, dysphagia, increased peristalsis, increased salivary
and gastric secretions, nausea, vomiting
-
GU:
Frequency, incontinence, urgency
-
MS:
arthralgia, fasciculations, muscle cramps and spasms, weakness
-
RESP:
bronchospasm, dyspnea, laryngospasm, respiratory arrest, respiratory
depression, increased tracheobronchial secretions
-
SKIN:
rash, urticaria
|
Dosage:
Administered
IV/IM
-
Adult:
-
Diagnosis
of myasthenia gravis:
-
IV
1-2mg over 15-30 seconds, then
8mg if no response
-
IM
10mg; if cholinergic reaction occurs, retest after ½ hour
with 2mg IM
-
Evaluation
of treatment requirements in myasthenia gravis:
-
IV 1-2mg 1 hour after PO dose of anticholinesterase
-
if strength improves, an increase in neostigmine or
pyridostigmine is indicated
-
Differentiation
of myasthenic crisis from cholinergic crisis:
-
IV 1mg, if no response in 1 minute, may repeat
-
myasthenic crisis clear improvement in
respiration
-
cholinergic crisis increased oropharyngeal
secretions and further weakening of respiratory muscles (intubation
and controlled respiration may be required)
-
Curare
antagonist:
-
Child:
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|